|
|
Neurocrine Biosciences, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: question KG also mentioned that a lot of the growth is from prescribers going deeper into their patient base, which was something he talked about in the past. Essentially the theory is that the prescribers were essentially testing for the efficacy of Ingrezza and now believe in it. This could be where Rx growth comes from this quarter.
|
|||||||||||||||||
|
|
return to message board, top of board |
